# US 2024/0189458 A1 · Methods for in vivo delivery of microbes to human microenvironments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189458 A1
- Document ID: US20240189458A1
- Status: Published application
- Kind: A1
- Application number: 18/570,949
- Filed: 2022-06-15
- Published: 2024-06-13
- Earliest claimed: 2021-06-15
- Assignees: William Marsh Rice University; Baylor College of Medicine
- Applicants: William Marsh Rice University; Baylor College of Medicine
- Inventors: Jeffrey TABOR; Omid VEISEH; Robert BRITTON; Moshe BARUCH; Annie GOODWIN; Elena MUSTEATA; Michael DOERFERT; Samira AGHLARA-FOTOVAT; Maxwell HUNT
- Web page: https://patentgrep.com/patent/US20240189458A1

## CPC

- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- C12N 1/20: Bacteria; Culture media therefor
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61K 9/5036: {Polysaccharides, e.g. gums, alginate; Cyclodextrin}
- A61K 9/5094: {Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting}
- A61K 9/5115: {Inorganic compounds}
- A61K 35/66: Microorganisms or materials therefrom (fungi, yeasts or candida A61K36/06)
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 49/0091: {Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer}
- C12N 11/04: entrapped within the carrier, e.g. gel or hollow fibres
- C12N 11/10: the carrier being a carbohydrate
- G01N 2800/065: Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure provides compositions comprising encapsulated engineered bacteria. The bacteria may be engineered to act as sensors of biomarkers, such as inflammation, as well as to produce diagnostic or therapeutic agents.

## Claims

### Claim 1

A device comprising engineered bacteria encapsulated in a hydrogel matrix.

### Claim 2 (depends on 1)

The device of claim 1, wherein the engineered bacteria is further defined as an engineered bacterial biosensor.

### Claim 3 (depends on 1)

The device of claim 1, wherein the hydrogel matrix comprises alginate.

### Claim 4 (depends on 3)

The device of claim 3, wherein the alginate is present at a concentration of 0.1-10 weight percent.

### Claim 5 (depends on 1)

The device of claim 1, wherein the hydrogel matrix is paramagnetic.

### Claim 6 (depends on 5)

The device of claim 5, wherein the hydrogel matrix further comprises a magnetic small molecule or nanoscale material.

### Claim 7 (depends on 6)

The device of claim 6, wherein the nanoscale material is a metal oxide or metal-based agent.

### Claim 8 (depends on 7)

The device of claim 7, wherein the metal oxide is titanium oxide, iron oxide, or ferrite.

### Claim 9 (depends on 8)

The device of claim 8, wherein the metal-based agent is ferric ammonium citrate.

### Claim 10 (depends on 5)

The device of claim 5, wherein the hydrogel matrix further comprises iron oxide.

### Claim 11 (depends on 1)

The device of claim 1, wherein the hydrogel matrix further comprises an ultraviolet (UV) absorbent small molecule.

### Claim 12 (depends on 11)

The device of claim 11, wherein the UV absorbent small molecule is a dye, photoabsorber, or photoblocker.

### Claim 13 (depends on 11)

The device of claim 11, wherein the UV absorbent small molecule is tartrazine (Yellow 5).

### Claim 14 (depends on 11)

The device of claim 11, wherein the UV absorbent nanoscale material is a metallic crystal, synthetic polymer, natural polymer, or carbon-based material.

### Claim 15 (depends on 11)

The device of claim 11, wherein the UV absorbent nanoscale material is titanium oxide.

### Claim 16 (depends on 1)

The device of claim 1, wherein the UV absorbent molecule is attached to alginate.

### Claim 17 (depends on 1)

The device of claim 1, wherein the hydrogel matrix is crosslinked with barium cations.

### Claim 18 (depends on 1)

The device of claim 1, wherein the hydrogel matrix comprises polyacrylamide, polyethylene glycol (PEG), polyethylene glycol diacrylate (PEGDA), or chitosan.

### Claim 19 (depends on 1)

The device of claim 1, wherein the hydrogel matrix comprises alginate and polyacrylamide.

### Claim 20 (depends on 19)

The device of claim 19, wherein the polyacrylamide and alginate are present at a ratio of 30:1 to 0.1:1.

### Claim 21 (depends on 19)

The device of claim 19, wherein the polyacrylamide and alginate are present at a ratio of 20:1, 10:1, or 5:1.

### Claim 22 (depends on 19)

The device of claim 19, wherein the hydrogel matrix comprises alginate and PEGDA.

### Claim 23 (depends on 22)

The device of claim 22, wherein the PEGDA and alginate are present at a ratio of 10:1 to 0.5:1.

### Claim 24 (depends on 1)

The device of claim 1, wherein the hydrogel comprises tetramethylethylenediamine (TEMED).

### Claim 25 (depends on 24)

The device of claim 24, wherein the TEMED is present at a concentration of 0.1% to 30% by volume.

### Claim 26 (depends on 24)

The device of claim 24, wherein the TEMED is present at a concentration of 0.1% by volume

### Claim 27 (depends on 1)

The device of claim 1, wherein the device comprises an inner core and outer shell.

### Claim 28 (depends on 1)

The device of claim 1, wherein the device is in a sphere confirmation.

### Claim 29 (depends on 1)

The device of claim 1, wherein the device is in a cylindrical noodle confirmation.

### Claim 30 (depends on 27)

The device of claim 27, wherein the engineered bacteria is in the inner core.

### Claim 31 (depends on 27)

The device of claim 27, wherein the outer shell is semi-permeable.

### Claim 32 (depends on 27)

The device of claim 27, wherein the outer shell comprises a semi-permeable polymer.

### Claim 33 (depends on 27)

The device of claim 27, wherein the outer shell is permeable to molecules under 500 kDa.

### Claim 34 (depends on 1)

The device of claim 1, wherein the hydrogel matrix is chemically modified.

### Claim 35 (depends on 1)

The device of claim 1, wherein the hydrogel matric has a specific density of chemical modifications.

### Claim 36 (depends on 35)

The device of claim 35, wherein the modification is an oligosaccharide, bacteriocidal molecule, bacteriostatic molecule, or a DNA vector that is transmitted into the host cell cytoplasm enabling expression of a gene in the host cell.

### Claim 37 (depends on 35)

The device of claim 35, wherein the chemical modification has a targeted density between 0 and 5 mmol per gram of alginate in the hydrogel matrix.

### Claim 38 (depends on 1)

The device of claim 1, wherein the hydrogel matrix is formulated to promote cell-material interactions between the semi-permeable polymer and the engineered bacteria.

### Claim 39 (depends on 38)

The device of claim 38, wherein the matrix has one or more chemical components to promote cell-material interactions.

### Claim 40 (depends on 39)

The device of claim 39, wherein the one or more chemical components comprise an adhesive peptide or substrate.

### Claim 41 (depends on 40)

The device of claim 40, wherein the adhesive peptide is fibronectin.

### Claim 42 (depends on 40)

The device of claim 40, wherein the substrate is xantham gum.

### Claim 43 (depends on 2)

The device of claim 2, wherein the engineered bacterial biosensor is genetically engineered to sense a physiological chemical or physical signal.

### Claim 44 (depends on 2)

The device of claim 2, wherein the engineered bacterial biosensor responds to one or more biomarkers of intestinal inflammation.

### Claim 45 (depends on 44)

The device of claim 44, wherein the biomarker of intestinal inflammation is thiosulfate, tetrathionate, nitrate, trimethyl amine N-oxide, calprotectin, kynurenine, reactive oxygen species, reactive nitrogen species, substance P, CCL20, or acidic pH.

### Claim 46 (depends on 2)

The device of claim 2, wherein the engineered bacterial biosensor comprises a one-component cytoplasmic protein capable of sensing ligands in the cytoplasm.

### Claim 47 (depends on 46)

The device of claim 46, wherein the one-component cytoplasmic protein capable of sensing ligands in the cytoplasm is SoxS or KynR.

### Claim 48 (depends on 2)

The device of claim 2, wherein the engineered bacterial biosensor comprises a membrane-bound two-component system.

### Claim 49 (depends on 48)

The device of claim 48, wherein the two-component system comprises ligand-induced signaling and regulation of gene expression by communicating with cytoplasmic proteins.

### Claim 50 (depends on 48)

The device of claim 48, wherein the two-component system detects pH, cadaverine, putrescine, nitrite, sialic acid, cellulose, estradiol, testosterone, androstenedione, or human antimicrobial peptides.

### Claim 51 (depends on 48)

The device of claim 48, wherein the two-component system is a PhoPQ two-component system.

### Claim 52 (depends on 51)

The device of claim 51, wherein the PhoPQ two-component system detects human microbial peptides (AMPs).

### Claim 53 (depends on 53)

The device of claim 53, wherein the AMPs are RK-31, KS-27, KS-30, TLN-58, LL-29, ALL-38, GNLY, CCL20, TCP, KR-20, CCL-19, hBD3, and/or NPY.

### Claim 54 (depends on 48)

The device of claim 48, wherein the two-component system is a ThsSR, TtrSR, NarXL, TorTSR, PhoPQ, or SO_4387-SO_4388REC-PsdRDBD 137 two-component system.

### Claim 55 (depends on 1)

The device of claim 1, wherein the engineered bacteria is an Escherichia coli, Lactobacillus reuteri, Lactobacillus crispatus, Lactobacillus rhamnosus, Lactobacillus crispatus, Lactococcus lactis, Bacteroides thetaiotamicron, or Bacillus subtilis bacterium.

### Claim 56 (depends on 1)

The device of claim 1, wherein the engineered bacteria comprises at least two strains of bacteria.

### Claim 57 (depends on 56)

The device of claim 56, wherein the at least two strains of bacteria can communicate using acyl homoserine lactones, autoinducer peptides, or other interbacterial communication signals.

### Claim 58 (depends on 55)

The device of claim 55, wherein the Escherichia coli is further defined as Escherichia coli Nissle 1917.

### Claim 59 (depends on 2)

The device of claim 2, wherein the engineered bacterial biosensor can compute sensory information and respond to the environment outside the construct to activate gene expression directly or activate an engineered genetic circuit that activates gene expression.

### Claim 60 (depends on 59)

The device of claim 59, wherein the engineered bacterial biosensor comprises SO_4387-SO_4388REC-PsdRDBD 137 to detect acidic pH and activate expression of a reporter gene or a T7 RNA polymerase to activates production of the reporter gene.

### Claim 61 (depends on 2)

The device of claim 2, wherein the engineered bacterial biosensor can respond to a signal by extracellular secretion of a molecule, production of a molecule that diffuses extracellularly, or cell lysis that releases molecules extracellularly.

### Claim 62 (depends on 61)

The device of claim 61, wherein the engineered bacterial biosensor secretes IL-22 through protein secretion machinery.

### Claim 63 (depends on 62)

The device of claim 62, wherein the protein secretion machinery comprises the Sec pathway, an acylhomoserine lactone that diffuses across the membrane, or the production of a phage lysin that induces cells lysis to result in spillage of IL-22.

### Claim 64 (depends on 1)

The device of claim 1, wherein the engineered bacteria expresses a cytokine, anti-NGF, bacteriocin, viral antigen, bacterial antigen, human allergen, monoclonal antibody, nanobody, bacterial quorum sensing molecule, viral vector, DNA, and/or RNA.

### Claim 65 (depends on 1)

The device of claim 1, wherein the engineered bacteria expresses at least one reporter.

### Claim 66 (depends on 65)

The device of claim 65, wherein the at least one reporter is selected from a chemiluminescent protein, a bioluminescent protein, a fluorescent protein, a colorimetric protein, a pigment-producing enzyme, or a barcoded messenger RNA.

### Claim 67 (depends on 65)

The device of claim 65, wherein the at least one reporter is sfGFP.

### Claim 68 (depends on 65)

The device of claim 65, wherein the at least one reporter is produced in response to ligand binding.

### Claim 69 (depends on 68)

The device of claim 68, wherein the engineered bacteria constitutively expresses a second reporter.

### Claim 70 (depends on 1)

The device of claim 1, wherein the engineered bacteria expresses a therapeutic agent.

### Claim 71 (depends on 70)

The device of claim 70, wherein the therapeutic agent is a protein.

### Claim 72 (depends on 70)

The device of claim 70, wherein the therapeutic agent is not a protein.

### Claim 73 (depends on 70)

The device of claim 70, wherein the therapeutic agent is an immune system modulator such as a cytokine, hormone, small molecule, insulin, glucagon, or statin.

### Claim 74 (depends on 73)

The device of claim 73, wherein the immune system modulator is a cytokine.

### Claim 75 (depends on 74)

The device of claim 74, wherein the cytokine is IL-1, IL-1α, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-15, IL-22, IL-28A, IL-19, IL-24, IL-29, IL-20, IL-28β, TGFβ, IL-12, IL-13, IL-16, IL-18, IFNα, IFNβ, IFNγ, TNFα, TNFβ, or IL-35.

### Claim 76 (depends on 70)

The device of claim 70, wherein the engineered bacteria can release the therapeutic agent.

### Claim 77 (depends on 76)

The device of claim 76, wherein the therapeutic agent has sustained or conditional release.

### Claim 78 (depends on 76)

The device of claim 76, wherein the therapeutic molecule has substantially non-pulsatile release.

### Claim 79 (depends on 1)

The device of claim 1, wherein the device comprises 101 to 1010 engineered bacteria.

### Claim 80 (depends on 1)

The device of claim 1, wherein each engineered bacteria is about 1 microns to about 3 microns in size.

### Claim 81 (depends on 1)

The device of claim 1, wherein the device comprises a degradable component.

### Claim 82 (depends on 81)

The device of claim 81, wherein the degradable component is a degradable alginate motif or one or more degradable crosslinkers.

### Claim 83 (depends on 82)

The device of claim 82, wherein the degradable alginate motif is partially oxidized alginate.

### Claim 84 (depends on 83)

The device of claim 83, wherein the one or more degradable crosslinkers are MMP-sensitive peptide crosslinkers.

### Claim 85 (depends on 81)

The device of claim 81, wherein the degradable component is an innate property of the construct material, a product of the material interacting with the in vivo environment, and/or a product of the construct's cellular components interacting directly or indirectly with the construct material.

### Claim 86 (depends on 81)

The device of claim 81, wherein the degradable component is in the inner zone and/or outer shell.

### Claim 87 (depends on 81)

The device of claim 81, wherein the degradable component is a degradable chemistry motif integrated into the hydrogel matrix as a part of the polymer and/or as a degradable crosslinker.

### Claim 88 (depends on 81)

The device of claim 81, wherein the degradable component is degradable is response to pH or an enzyme.

### Claim 89 (depends on 81)

The device of claim 81, wherein the degradable is degradable by the engineered bacteria and/or secreted cellular components.

### Claim 90 (depends on 1)

The device of claim 1, wherein the device is formulated for oral administration, implantation, inhalation, or injection.

### Claim 91 (depends on 1)

The device of claim 1, wherein the device is formulated for implantation.

### Claim 92 (depends on 1)

A method of treating a disease in a subject in need thereof comprising administering an effective amount of the device of claim 1 to the subject.

### Claim 93 (depends on 92)

The method of claim 92, wherein the disease is inflammatory bowel disease, Crohn's, ulcerative colitis, vaginal yeast infection, bacterial vaginosis, parasitic infection, appendicitis, lung cancer, acute respiratory distress syndrome, mesothelioma, thrush, or oral cancer.

### Claim 94 (depends on 93)

The method of claim 93, wherein the parasitic infection trichomoniasis.

### Claim 95 (depends on 92)

The method of claim 92, wherein the disease is Crohn's.

### Claim 96 (depends on 92)

The method of claim 92, wherein the disease is inflammatory bowel disease.

### Claim 97 (depends on 92)

The method of claim 92, wherein the disease is ulcerative colitis.

### Claim 98 (depends on 92)

The method of claim 92, further comprising monitoring inflammation in the subject.

### Claim 99 (depends on 98)

The method of claim 98, wherein monitoring inflammation comprises detecting a reporter produced by the engineered bacteria.

### Claim 100 (depends on 86)

The method of claim 86, wherein monitoring inflammation does not comprise an invasive procedure.

### Claim 101 (depends on 100)

The method of claim 100, wherein the invasive procedure is a colon biopsy or endoscopy.

### Claim 102 (depends on 98)

The method of claim 98, wherein monitoring inflammation comprises analysis of a fecal sample from said subject and performing flow cytometry to detect said reporter.

### Claim 103 (depends on 1)

A method of monitoring inflammation in a subject in need thereof comprising administering an effective amount of the device of claim 1 to the subject and detecting a reporter produced by the engineered bacteria.

### Claim 104 (depends on 103)

The method of claim 103, wherein the subject has inflammatory bowel disease.

### Claim 105 (depends on 103)

The method of claim 103, wherein the subject has Crohn's or ulcerative colitis.

### Claim 106 (depends on 103)

The method of claim 103, wherein monitoring inflammation does not comprise an invasive procedure.

### Claim 107 (depends on 106)

The method of claim 106, wherein the invasive procedure is a colon biopsy or endoscopy.

### Claim 108 (depends on 103)

The method of claim 103, wherein detecting comprises analysis of a fecal sample from said subject and performing flow cytometry to determine the level of said reporter.
